Question special
Lead Moderator

Over the past few days, many of you have expressed that cost may be a barrier to widespread implementation of this prognostic assay. Can you expand on your views as to why, and also where this cost may be justified? For example, can it result in healthcare savings by reducing potentially unnecessary chemotherapy?